| Issue |
BIO Web Conf.
Volume 198, 2025
5th ASEAN Microbial Biotechnology Conference (AMBC 2025)
|
|
|---|---|---|
| Article Number | 04004 | |
| Number of page(s) | 15 | |
| Section | Biotechnology | |
| DOI | https://doi.org/10.1051/bioconf/202519804004 | |
| Published online | 03 December 2025 | |
Investigating the anti-SARS-CoV-2 activity of caffeic acid: A combined network pharmacology and laboratory study
1 Department of Medicine, Faculty of Medicine and Health Science, UIN Maulana Malik Ibrahim Malang, 65151 East Java, Indonesia
2 Department of Public Health, Faculty of Medicine and Health Science, UIN Maulana Malik Ibrahim Malang, 65151 East Java, Indonesia
3 Department of Clinical Medicine, Faculty of Medicine and Health Science, UIN Maulana Malik Ibrahim Malang, 65151 East Java, Indonesia
4 Institute of Tropical Disease, Universitas Airlangga, Surabaya, 60115 East Java, Indonesia
* Corresponding author: This email address is being protected from spambots. You need JavaScript enabled to view it.
The COVID-19 pandemic necessitated the urgent identification of effective antiviral agents, with natural compounds such as caffeic acid (CA) emerging as candidates based on broad-spectrum antiviral action. While prior computational studies suggested prospective therapeutic activity against SARS-CoV-2, a systematic, integrated study validating CA's multi-target mechanism and functional efficacy was lacking. This study was to explore and validate the molecular targets and antiviral efficacy of caffeic acid against SARS-CoV-2. Network Pharmacology (NP) was employed using GeneCards, DisGeNET, and OMIM to identify multiple inflammation and entry-related targets including ACE2, TNF-á, and NLRP3. PPI analysis revealed a highly connected network, predicting that CA targets the Renin-Angiotensin System (RAS) and key inflammatory mediators. Caffeic acid showed weak antiviral activity against SARS-CoV-2 in vitro, with an IC50 of 278 ìÌ and SI > 1, which indicates weak activity according to antiviral screening standards and pharmacologically low potency. The predicted pathways may indeed be valid targets, but caffeic acid did not specifically affect the mechanisms contributing to the antiviral response. The weak activity measured may be due to non-specific interactions and not the pathways targeted by the predictions.
© The Authors, published by EDP Sciences, 2025
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.